<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>24008532</identifier>
<setSpec>1137-6627</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Saralegui, A</dc:author>
<dc:author>Royo, P</dc:author>
<dc:author>Palacio, P</dc:author>
<dc:description xml:lang="en">Asthenia (or fatigue) is one of the most common symptoms in palliative patients. Methylphenidate is currently being assessed for treating this condition. A review of related literature published to date was performed, revealing methylphenidate to be a safe drug which could decrease fatigue in palliative patients with a tolerable side-effects profile.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2013 Sep 06 </dc:date>
<dc:title xml:lang="es">Revisi√≥n sobre el uso del metilfenidato para el tratamiento de la astenia en pacientes paliativos.</dc:title>
<dc:title xml:lang="en">[Use of methylphenidate in palliative patients with asthenia: a review].</dc:title>
<dc:publisher>Anales del sistema sanitario de Navarra</dc:publisher>
</metadata>
</record>
</pubmed-document>
